232 related articles for article (PubMed ID: 23027067)
21. [Management of enzalutamide, a new hormonal therapy].
Beuzeboc P; Benderra MA; de La Motte Rouge T
Bull Cancer; 2014 Jan; 101(1):107-12. PubMed ID: 24491670
[TBL] [Abstract][Full Text] [Related]
22. [New endocrine treatments prolong survival of patients with castration-resistant prostate cancer].
Brasso K; Thomsen FB; Berg KD; Røder MA; Iversen P
Ugeskr Laeger; 2013 Sep; 175(40):2328-32. PubMed ID: 24079321
[TBL] [Abstract][Full Text] [Related]
23. Combined blockade of testicular and locally made androgens in prostate cancer: a highly significant medical progress based upon intracrinology.
Labrie F
J Steroid Biochem Mol Biol; 2015 Jan; 145():144-56. PubMed ID: 24925260
[TBL] [Abstract][Full Text] [Related]
24. Enzalutamide after docetaxel and abiraterone therapy in metastatic castration-resistant prostate cancer.
Schmid SC; Geith A; Böker A; Tauber R; Seitz AK; Kuczyk M; von Klot C; Gschwend JE; Merseburger AS; Retz M
Adv Ther; 2014 Feb; 31(2):234-41. PubMed ID: 24442834
[TBL] [Abstract][Full Text] [Related]
25. Enzalutamide for the treatment of castration-resistant prostate cancer.
Ha YS; Goodin S; DiPaola RS; Kim IY
Drugs Today (Barc); 2013 Jan; 49(1):7-13. PubMed ID: 23362491
[TBL] [Abstract][Full Text] [Related]
26. Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC).
Pal SK; Patel J; He M; Foulk B; Kraft K; Smirnov DA; Twardowski P; Kortylewski M; Bhargava V; Jones JO
Cancer; 2018 Mar; 124(6):1216-1224. PubMed ID: 29266182
[TBL] [Abstract][Full Text] [Related]
27. The role of enzalutamide in the treatment of castration-resistant prostate cancer.
Rawlinson A; Mohammed A; Miller M; Kunkler R
Future Oncol; 2012 Sep; 8(9):1073-81. PubMed ID: 23030482
[TBL] [Abstract][Full Text] [Related]
28. Androgen receptor directed therapies in castration-resistant metastatic prostate cancer.
Kim W; Ryan CJ
Curr Treat Options Oncol; 2012 Jun; 13(2):189-200. PubMed ID: 22539224
[TBL] [Abstract][Full Text] [Related]
29. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.
Cai C; Chen S; Ng P; Bubley GJ; Nelson PS; Mostaghel EA; Marck B; Matsumoto AM; Simon NI; Wang H; Chen S; Balk SP
Cancer Res; 2011 Oct; 71(20):6503-13. PubMed ID: 21868758
[TBL] [Abstract][Full Text] [Related]
30. The Effect of Time to Castration Resistance on Outcomes With Abiraterone and Enzalutamide in Metastatic Prostate Cancer.
Hung J; Taylor AR; Divine GW; Hafron JM; Hwang C
Clin Genitourin Cancer; 2016 Oct; 14(5):381-388. PubMed ID: 27157640
[TBL] [Abstract][Full Text] [Related]
31. Secondary hormonal manipulation in castration resistant prostate cancer.
Al-Asaaed S; Winquist E
Can J Urol; 2014 Apr; 21(2 Supp 1):37-41. PubMed ID: 24775722
[TBL] [Abstract][Full Text] [Related]
32. Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer.
Buttigliero C; Tucci M; Bertaglia V; Vignani F; Bironzo P; Di Maio M; Scagliotti GV
Cancer Treat Rev; 2015 Dec; 41(10):884-92. PubMed ID: 26342718
[TBL] [Abstract][Full Text] [Related]
33. [Effect and adverse event of enzalutamide and abiraterone in prostate cancer].
Kosaka T; Oya M
Nihon Rinsho; 2015 Feb; 73 Suppl 2():308-12. PubMed ID: 25831773
[No Abstract] [Full Text] [Related]
34. Abiraterone in prostate cancer: a new angle to an old problem.
Stein MN; Goodin S; Dipaola RS
Clin Cancer Res; 2012 Apr; 18(7):1848-54. PubMed ID: 22451619
[TBL] [Abstract][Full Text] [Related]
35. [Androgen-deprivation therapy in prostate cancer: clinical evidence and future perspectives].
Pinto F; Calarco A; Totaro A; Sacco E; Volpe A; Racioppi M; D'Addessi A; Bassi PF
Urologia; 2010; 77(2):71-83. PubMed ID: 20890863
[TBL] [Abstract][Full Text] [Related]
36. Overview of the latest treatments for castration-resistant prostate cancer.
Bishr M; Saad F
Nat Rev Urol; 2013 Sep; 10(9):522-8. PubMed ID: 23797341
[TBL] [Abstract][Full Text] [Related]
37. [Hormone therapy in prostate cancer; a pharmacotherapeutic challenge].
Westdorp H; Benoist GE; Schers HJ; van Erp PH; Gerritsen WR; Mulders PF; Kramers C
Ned Tijdschr Geneeskd; 2015; 159():A9250. PubMed ID: 26246066
[TBL] [Abstract][Full Text] [Related]
38. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.
Reid AH; Attard G; Danila DC; Oommen NB; Olmos D; Fong PC; Molife LR; Hunt J; Messiou C; Parker C; Dearnaley D; Swennenhuis JF; Terstappen LW; Lee G; Kheoh T; Molina A; Ryan CJ; Small E; Scher HI; de Bono JS
J Clin Oncol; 2010 Mar; 28(9):1489-95. PubMed ID: 20159823
[TBL] [Abstract][Full Text] [Related]
39. Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.
Payne H; Bahl A; Mason M; Troup J; De Bono J
BJU Int; 2012 Sep; 110(5):658-67. PubMed ID: 22429837
[TBL] [Abstract][Full Text] [Related]
40. Utility of novel androgen receptor therapies in the real world: A nuanced approach.
Dhawan M; Ryan CJ
Urol Oncol; 2016 Aug; 34(8):340-7. PubMed ID: 27450893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
